John Buse's guest appearances

John Buse

Focus with Paul W. Smith

HealthyBites with Dr. Susan Spratt

Chair's Corner with Dr. Ron Falk

Diabetes Knowledge into Practice Podcast

Jennifer Green

Tom Campbell

Kamala Harris

Sean Spicer

Kevin Ward

Joel Kahn

Brad Meltzer

Jason Scott

Jimmie Johnson

Dan Miller

Bernie Sanders

David Katz

Mitch Albom

Dave Smith

P.J. O'Rourke

OwlTail

The first appointment following a diabetes diagnosis is an important opportunity to begin an optimal management plan. Through a patient-centred approach, this should include discussion of the patient’s personal goals and circumstances, and education on the importance of glycaemic control. To help us put this into practice we are joined by Dr John Buse, Professor of Medicine at the University of North Carolina School of Medicine, and author of the ADA and EASD consensus report on the management of hyperglycaemia in type 2 diabetes. For more free education, visit the DKIP website, follow us on Twitter (@dkipractice) or connect on LinkedIn. References - Khunti, et al. Prim Care Diabetes. 2017;11(1):3-12 - Paul, et al. Cardiovasc Diabetol. 2015;14:100 - Davies, at al. Diabetologia. 2018;61(12):2461-2498 - Buse, et al. Diabetes Care. 2020;43(2):487-493 - Matthews, et al. Lancet. 2019;394(10208):1519-1529 Disclosures: Dr John Buse declares consulting fees and travel support (paid to the University of North Carolina) from Adocia, AstraZeneca, Dance Biopharm, Eli Lilly, Fortress Biotech, MannKind, NovaTarg, Novo Nordisk, Sanofi, Senseonics, vTv Therapeutics, and Zafgen; consulting fees from Cirius Therapeutics Inc, CSL Behring, Fortress Biotech, Mellitus Health, Moderna, Neurimmune AG, Pendulum Therapeutics, Stability Health and Zealand Pharma; stock options in Mellitus Health, Pendulum Therapeutics, PhaseBio, and Stability Health; grant support from NovaTarg, Novo Nordisk, Sanofi, Tolerion and vTv Therapeutics. Funding statement: This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp &amp; Dohme Corp and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

The first appointment following a diabetes diagnosis is an important opportunity to begin an optimal management plan. Through a patient-centred approach, this should include discussion of the patient’s personal goals and circumstances, and education on the importance of glycaemic control. To help us put this into practice we are joined by Dr John Buse, Professor of Medicine at the University of North Carolina School of Medicine, and author of the ADA and EASD consensus report on the management of hyperglycaemia in type 2 diabetes. For more free education, visit the <a href="https://sso.knowledgeinpractice.eu/" rel="nofollow" target="_blank">DKIP website</a>, follow us on Twitter (<a href="https://twitter.com/dkipractice" rel="nofollow" target="_blank">@dkipractice</a>) or connect on <a href="https://www.linkedin.com/" rel="nofollow" target="_blank">LinkedIn</a>. References - <a href="https://pubmed.ncbi.nlm.nih.gov/27727005/" rel="nofollow" target="_blank">Khunti, et al. Prim Care Diabetes. 2017;11(1):3-12</a> - <a href="https://pubmed.ncbi.nlm.nih.gov/26249018/" rel="nofollow" target="_blank">Paul, et al. Cardiovasc Diabetol. 2015;14:100</a> - <a href="https://pubmed.ncbi.nlm.nih.gov/30288571/" rel="nofollow" target="_blank">Davies, at al. Diabetologia. 2018;61(12):2461-2498</a> - <a href="https://pubmed.ncbi.nlm.nih.gov/31857443/" rel="nofollow" target="_blank">Buse, et al. Diabetes Care. 2020;43(2):487-493</a> - <a href="https://pubmed.ncbi.nlm.nih.gov/31542292/" rel="nofollow" target="_blank">Matthews, et al. Lancet. 2019;394(10208):1519-1529</a> Disclosures: Dr John Buse declares consulting fees and travel support (paid to the University of North Carolina) from Adocia, AstraZeneca, Dance Biopharm, Eli Lilly, Fortress Biotech, MannKind, NovaTarg, Novo Nordisk, Sanofi, Senseonics, vTv Therapeutics, and Zafgen; consulting fees from Cirius Therapeutics Inc, CSL Behring, Fortress Biotech, Mellitus Health, Moderna, Neurimmune AG, Pendulum Therapeutics, Stability Health and Zealand Pharma; stock options in Mellitus Health, Pendulum Therapeutics, PhaseBio, and Stability Health; grant support from NovaTarg, Novo Nordisk, Sanofi, Tolerion and vTv Therapeutics. Funding statement: This independent educational activity is supported by an educational grant from Eli Lilly, Merck Sharp &amp; Dohme Corp and Novo Nordisk A/S. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; the financial supporters have had no influence on the content of this education.

The pivotal first appointment | With Dr John Buse

Dr. John Buse, Chief, Division of Endocrinology, Director of North Carolina Translational and Clinical Sciences Institute, Executive Associate Dean, Clinical Research University of North Carolina School of Medicine.

Dr. John Buse - 5/5/20

Dr. John Buse shares what is new in the treatment of diabetes, and highlights the benefits that SGLT2 inhibitors and GLP-1 receptor agonists can offer to patients, among other topics related to diabetes treatment.

New Diabetes Treatments - with Dr. John Buse


Episode 6 - New Emerging Therapies And Research (Dr. John Buse) by DukeWELL

Episode 6 - New Emerging Therapies And Research (Dr. John Buse)